TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07221838: A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

Sponsor: Alexion Pharmaceuticals, Inc. · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 75 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,301,440

Rescue Site Savings

+$849,920

Unlock Full NCT07221838 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07221838 Rescue Dossier →